Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Belinostat: Phase I started

Spectrum began the open-label, dose-escalation, U.S. Phase I BelCHOP trial to evaluate belinostat in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE